Clustered peptide regulating the multivalent interaction between RANK and TRAF6 inhibits osteoclastogenesis by...

Area of Science:

• Biochemistry
• Cell Biology
• Immunology

Background:

• Bone-destructive diseases result from uncontrolled osteoclastogenesis.
• Osteoclast differentiation is regulated by the RANKL-RANK signaling pathway.
• TRAF6 acts as a crucial adapter molecule in RANK signaling.

Purpose of the Study:

• To identify novel modulators of TRAF6-mediated signaling.
• To develop a therapeutic agent targeting osteoclastogenesis.
• To investigate the mechanism of CR4-WHD-tet in inhibiting osteoclast differentiation.

Main Methods:

• Affinity-based screening of a multivalent random-peptide library.
• Identification of a tetravalent peptide (WHD-tet) targeting TRAF6.
• In vitro assessment of cell-permeable CR4-WHD-tet on bone-marrow cell differentiation.
• In vivo evaluation of CR4-WHD-tet in a mouse model of osteoclastogenesis.
• Analysis of specific molecular interactions and signaling pathway modulation.

Main Results:

• A tetravalent peptide, WHD-tet, was identified that binds to the RANK-binding region of TRAF6.
• Cell-permeable CR4-WHD-tet significantly inhibited RANKL-induced osteoclast differentiation and osteoclastogenesis in vivo.
• CR4-WHD-tet specifically disrupted the recruitment of MAPK kinase 3 to TRAF6.
• This targeted inhibition affected the p38-MAPK pathway, crucial for late-stage osteoclast differentiation.

Conclusions:

• CR4-WHD-tet is a potent inhibitor of osteoclastogenesis.
• The peptide acts by fine-tuning the formation of a critical signaling complex involving TRAF6.
• CR4-WHD-tet represents a promising therapeutic candidate for bone-destructive diseases.